|
23 Jun 2009 - GSK and Chroma form alliance to develop novel macrophage-targeted therapeutics
GlaxoSmithKline (LSE: GSK) and Chroma Therapeutics Limited, announced today a collaboration to develop macrophage-targeted compounds using Chroma’s proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targetting the compounds to specific cells in the inflammatory disease process.
complete article »
|
16 Jun 2009 - ChemoCentryx's novel Crohn's drug passes first stage of Phase II/III trial
Initial results from a Phase II/III trial show that ChemoCentryx's novel lead compound Traficet-EN (CCX282-B), which is being co-developed with GlaxoSmithKline, demonstrates preliminary efficacy and good tolerability for patients with moderate to severe Crohn's disease. Traficet-EN is an oral antagonist of the CCR9 chemokine receptor.
complete article »
|